APA-referens

Bear, H. D., Tang, G., Rastogi, P., Geyer, C. E., Liu, Q., Robidoux, A., . . . Wolmark, N. (2015). Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): Secondary outcomes of a phase 3, randomised controlled trial. Lancet Oncol.

Chicago-stil citat

Bear, Harry D., et al. "Neoadjuvant Plus Adjuvant Bevacizumab in Early Breast Cancer (NSABP B-40 [NRG Oncology]): Secondary Outcomes of a Phase 3, Randomised Controlled Trial." Lancet Oncol 2015.

MLA-referens

Bear, Harry D., et al. "Neoadjuvant Plus Adjuvant Bevacizumab in Early Breast Cancer (NSABP B-40 [NRG Oncology]): Secondary Outcomes of a Phase 3, Randomised Controlled Trial." Lancet Oncol 2015.

Varning: dessa hänvisningar är inte alltid fullständigt riktiga.